CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social

This filing is only material insofar as it flags ongoing capital-structure drift in a very small, pre-commercial biotech. In names like this, even low-single-digit monthly share creep matters because it creates a standing supply overhang: every incremental issuance reduces the torque from any future regulatory headline and forces a larger fundamental rerating just to keep the stock flat.

The bigger issue is not the share-count change itself but what it implies about funding runway. A BARDA-backed program improves survivability, but it does not remove dilution risk if the company still needs bridge capital to get from regulatory progress to monetization. Over the next 1-3 months, the equity can stay pinned if the market believes additional issuance is more likely than a clean de-risking event; over 6-18 months, the key question is whether government support translates into non-dilutive validation or merely extends the timeline.

Contrarian view: the market often treats public funding as a quasi-guarantee of value, but in practice it can just prolong the binary phase while common holders absorb the financing cost. The important falsifier is not another routine filing; it is a break in the pattern, such as a substantive regulatory approval, a meaningful commercial contract, or explicit evidence that share count has stabilized. Absent that, this is more of a watchlist item than a tradable catalyst.